ANTARES PHARMA INC's ticker is ATRS and the CUSIP is 036642106. A total of 160 filers reported holding ANTARES PHARMA INC in Q2 2020. The put-call ratio across all filers is 2.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,820,000 | -16.5% | 500,000 | 0.0% | 3.59% | -17.3% |
| Q2 2021 | $2,180,000 | +6.1% | 500,000 | 0.0% | 4.34% | -5.1% |
| Q1 2021 | $2,055,000 | +3.0% | 500,000 | 0.0% | 4.58% | -31.9% |
| Q4 2020 | $1,995,000 | +47.8% | 500,000 | 0.0% | 6.72% | +51.1% |
| Q3 2020 | $1,350,000 | -1.8% | 500,000 | 0.0% | 4.45% | +26.7% |
| Q2 2020 | $1,375,000 | +16.5% | 500,000 | 0.0% | 3.51% | +76.9% |
| Q1 2020 | $1,180,000 | -16.3% | 500,000 | +66.7% | 1.98% | -52.2% |
| Q4 2019 | $1,410,000 | +5.4% | 300,000 | -25.0% | 4.15% | +71.8% |
| Q3 2019 | $1,338,000 | +103.3% | 400,000 | +100.0% | 2.42% | +95.8% |
| Q2 2019 | $658,000 | -13.2% | 200,000 | -20.0% | 1.23% | -57.7% |
| Q1 2019 | $758,000 | +11.5% | 250,000 | 0.0% | 2.92% | +10.5% |
| Q4 2018 | $680,000 | -19.0% | 250,000 | 0.0% | 2.64% | +30.1% |
| Q3 2018 | $840,000 | +62.8% | 250,000 | +25.0% | 2.03% | +38.9% |
| Q2 2018 | $516,000 | – | 200,000 | – | 1.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sargent Investment Group, LLC | 4,598,329 | $10,852,000 | 4.99% |
| Soleus Capital Management, L.P. | 864,100 | $2,039,000 | 2.37% |
| Healthcare Value Capital, LLC | 500,000 | $1,180,000 | 1.98% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,227,114 | $2,896,000 | 0.86% |
| PERKINS CAPITAL MANAGEMENT INC | 232,166 | $548,000 | 0.66% |
| Stonepine Capital Management, LLC | 151,189 | $357,000 | 0.38% |
| Zebra Capital Management LLC | 84,963 | $200,000 | 0.32% |
| Intrinsic Edge Capital Management LLC | 1,000,000 | $2,360,000 | 0.31% |
| Alambic Investment Management, L.P. | 46,069 | $109,000 | 0.26% |
| OBERWEIS ASSET MANAGEMENT INC/ | 200,600 | $473,000 | 0.26% |